Our results demonstrate that the combination of DRD4 antagonism and CB2R agonism effectively reduces binge-like intake of PF, presenting a novel potential therapeutic approach for BED. The gene discussed is DRD4; the disease is X-linked cone dysfunction syndrome with myopia.